Villere ST Denis J & Co. LLC Has $24.73 Million Stock Position in Stryker Corporation $SYK

Villere ST Denis J & Co. LLC lessened its stake in Stryker Corporation (NYSE:SYK) by 3.3% in the 1st quarter, HoldingsChannel reports. The fund owned 75,264 shares of the medical technology company’s stock after selling 2,595 shares during the quarter. Stryker accounts for about 2.7% of Villere ST Denis J & Co. LLC’s holdings, making the stock its 11th biggest holding. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $24,731,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $26,000. Sankala Group LLC bought a new position in Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker during the fourth quarter worth $28,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 0.8%

Shares of NYSE:SYK traded up $2.75 during mid-day trading on Friday, reaching $329.86. The stock had a trading volume of 2,724,614 shares, compared to its average volume of 2,471,298. The firm has a 50 day simple moving average of $310.12 and a two-hundred day simple moving average of $337.97. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The firm has a market cap of $126.46 billion, a PE ratio of 38.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday. Finally, Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $392.87.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.